AGRANULOCYTOSIS AND MACULOPAPULAR RASH AFTER TREATMENT WITH TICLOPIDINE – CASE REPORT
<p>Background. Ticlopidine is one of inhibitors of platelet aggregation indicated for reducing the risk of thrombotic stroke in patients who have experienced thrombotic stroke, ischemic attacks, unstable angina pectoris, coronary artery stenting and peripheral vascular bypass grafting. The wea...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Slovenian Medical Association
2003-01-01
|
Series: | Zdravniški Vestnik |
Subjects: | |
Online Access: | http://vestnik.szd.si/index.php/ZdravVest/article/view/1778 |
id |
doaj-7858e763c9574406bf8739d72c2b2358 |
---|---|
record_format |
Article |
spelling |
doaj-7858e763c9574406bf8739d72c2b23582020-11-24T20:50:06ZengSlovenian Medical AssociationZdravniški Vestnik1318-03471581-02242003-01-017211286AGRANULOCYTOSIS AND MACULOPAPULAR RASH AFTER TREATMENT WITH TICLOPIDINE – CASE REPORTJanja Blatnik0Gorazd Lešničar1Branko Šibanc2Stella Cvitan3Harry Strokol4Oddelek za infekcijske bolezni in vročinska stanja Splošna bolnišnica Celje Oblakova ulica 5 3000 CeljeOddelek za infekcijske bolezni in vročinska stanja Splošna bolnišnica Celje Oblakova ulica 5 3000 CeljeOddelek za infekcijske bolezni in vročinska stanja Splošna bolnišnica Celje Oblakova ulica 5 3000 CeljeOddelek za infekcijske bolezni in vročinska stanja Splošna bolnišnica Celje Oblakova ulica 5 3000 CeljeOddelek za sistemske in presnovne bolezni Splošna bolnišnica Celje Oblakova ulica 5 3000 Celje<p>Background. Ticlopidine is one of inhibitors of platelet aggregation indicated for reducing the risk of thrombotic stroke in patients who have experienced thrombotic stroke, ischemic attacks, unstable angina pectoris, coronary artery stenting and peripheral vascular bypass grafting. The weak point of this treatment are many serious adverse effects, the most serious of them being neutropenia.</p><p>Patient and therapy. We report a case of a 70-years old woman who developed agranulocytosis and skin rash by the end of the 4-week therapy with ticlopidine. After discontinued therapy with ticlopidine and when lenograstim was administered, agranulocytosis, anemia and rash subsided in one week.</p><p>Conclusions. As ticlopidine is associated with serious complications, its application has to be reserved for those patients who are intolerant to aspirin therapy.</p>http://vestnik.szd.si/index.php/ZdravVest/article/view/1778platelet aggregation inhibitorneutropeniaagranulocytosisthrombocytopeniaanemia |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Janja Blatnik Gorazd Lešničar Branko Šibanc Stella Cvitan Harry Strokol |
spellingShingle |
Janja Blatnik Gorazd Lešničar Branko Šibanc Stella Cvitan Harry Strokol AGRANULOCYTOSIS AND MACULOPAPULAR RASH AFTER TREATMENT WITH TICLOPIDINE – CASE REPORT Zdravniški Vestnik platelet aggregation inhibitor neutropenia agranulocytosis thrombocytopenia anemia |
author_facet |
Janja Blatnik Gorazd Lešničar Branko Šibanc Stella Cvitan Harry Strokol |
author_sort |
Janja Blatnik |
title |
AGRANULOCYTOSIS AND MACULOPAPULAR RASH AFTER TREATMENT WITH TICLOPIDINE – CASE REPORT |
title_short |
AGRANULOCYTOSIS AND MACULOPAPULAR RASH AFTER TREATMENT WITH TICLOPIDINE – CASE REPORT |
title_full |
AGRANULOCYTOSIS AND MACULOPAPULAR RASH AFTER TREATMENT WITH TICLOPIDINE – CASE REPORT |
title_fullStr |
AGRANULOCYTOSIS AND MACULOPAPULAR RASH AFTER TREATMENT WITH TICLOPIDINE – CASE REPORT |
title_full_unstemmed |
AGRANULOCYTOSIS AND MACULOPAPULAR RASH AFTER TREATMENT WITH TICLOPIDINE – CASE REPORT |
title_sort |
agranulocytosis and maculopapular rash after treatment with ticlopidine – case report |
publisher |
Slovenian Medical Association |
series |
Zdravniški Vestnik |
issn |
1318-0347 1581-0224 |
publishDate |
2003-01-01 |
description |
<p>Background. Ticlopidine is one of inhibitors of platelet aggregation indicated for reducing the risk of thrombotic stroke in patients who have experienced thrombotic stroke, ischemic attacks, unstable angina pectoris, coronary artery stenting and peripheral vascular bypass grafting. The weak point of this treatment are many serious adverse effects, the most serious of them being neutropenia.</p><p>Patient and therapy. We report a case of a 70-years old woman who developed agranulocytosis and skin rash by the end of the 4-week therapy with ticlopidine. After discontinued therapy with ticlopidine and when lenograstim was administered, agranulocytosis, anemia and rash subsided in one week.</p><p>Conclusions. As ticlopidine is associated with serious complications, its application has to be reserved for those patients who are intolerant to aspirin therapy.</p> |
topic |
platelet aggregation inhibitor neutropenia agranulocytosis thrombocytopenia anemia |
url |
http://vestnik.szd.si/index.php/ZdravVest/article/view/1778 |
work_keys_str_mv |
AT janjablatnik agranulocytosisandmaculopapularrashaftertreatmentwithticlopidinecasereport AT gorazdlesnicar agranulocytosisandmaculopapularrashaftertreatmentwithticlopidinecasereport AT brankosibanc agranulocytosisandmaculopapularrashaftertreatmentwithticlopidinecasereport AT stellacvitan agranulocytosisandmaculopapularrashaftertreatmentwithticlopidinecasereport AT harrystrokol agranulocytosisandmaculopapularrashaftertreatmentwithticlopidinecasereport |
_version_ |
1716804781821919232 |